McKesson’s (MCK Quick QuoteMCK - Free Report) prospects are being driven by robust growth in specialty distribution, oncology services and biopharma solutions. Earnings are also improving on the back of ongoing operational efficiency and capital discipline despite persistent margin pressures and volatility across certain segments.

Shares of this Zacks Rank #3 (Hold) company have gained 4.4% so far this year compared with the industry's 2% rise. The S&P 500 has increased 12.7% in the said time frame.

MCK is one of the leading pharmaceutical distributors in North America, with a market capitalization of $88.46 billion. It forecasts 13.7% earnings growth over the next five years. The company’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 3.09%.

Image Source: Zacks Investment Research

Factors Favoring MCK Stock

Broad-Based Growth Is Strengthening McKesson’s Earnings: McKesson’s performance in the first quarter of fiscal 2027 demonstrated that earnings momentum is not dependent on a single business. Revenues increased 8% to $105.4 billion, while adjusted EPS rose 20% to $9.93. North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions all delivered double-digit operating-profit growth.

Management said June was the strongest month of the quarter, suggesting positive momentum exiting the first quarter. The company subsequently raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00, implying 15-17% growth at the midpoint. Growth across major segmentsgives McKesson multiple avenues to sustain earnings growth even if individual product categories experience volatility.

Oncology & Multispecialty Is Becoming a Major Growth Accelerator: Oncology & Multispecialty delivered exceptional first-quarter momentum, with revenues rising 33% to $14.2 billion and operating profit increasing 41%. Even excluding the Core Ventures acquisition, revenues grew approximately 24%, indicating that organic expansion remains substantial.

Management attributed the performance to higher specialty-distribution volumes, penetration of existing provider relationships and new-business wins. The U.S. Oncology Network now includes approximately 3,400 providers, while the broader specialty platform serves more than 14,000 providers. With stable patient utilization, physician recruitment, geographic expansion and additional services creating cross-selling opportunities, management expects 14.5-18.5% revenue growth for the segment in fiscal 2027.

GLP-1 Distribution Is Creating Significant Volume Tailwinds: McKesson’s exposure to GLP-1 therapies is boosting topline significantly. North American Pharmaceutical generated $15 billion of GLP-1 distribution revenues in the first quarter, more than 14% of total revenues. GLP-1 sales were up approximately 24% year over year and 13% sequentially. Management expects GLP-1 volumes to continue growing throughout fiscal 2027, although quarterly variability is likely.

Growth across both covered and other channels suggests that demand extends beyond any single reimbursement mechanism. Prescription Technology Solutions is also benefiting from GLP-1 demand through access and affordability services. This creates a complementary growth model in which McKesson can participate through both pharmaceutical distribution and technology-enabled patient access.

Factors That May Offset the Gains for MCK

Branded Drug Price Declines and Generic Conversion Pressure Growth: North American Pharmaceutical revenues increased 5%, but growth was partially offset by lower branded pharmaceutical pricing following January 2026 WAC reductions and branded-to-generic conversions. McKesson emphasized that these pricing changes have a limited impact on operating profit because more than 95% of branded drugs are sold under fee-for-service arrangements, although the effect on reported revenues remains significant. Since pharmaceutical distribution revenues are recognized based on drug selling prices, further WAC reductions could suppress headline revenue growth even when prescription volumes remain healthy.

Medical-Surgical Solutions Faces Low Growth, Margin Pressure: Medical-Surgical Solutions improved its revenue trajectory in the fiscal first quarter, but the segment remains a drag on McKesson’s consolidated earnings profile. Revenues increased only 4% to $2.8 billion, while operating profit declined 20% to $195 million.

Management attributed the earnings decline to product mix and a one-time administrative expense, partially offset by extended-care contributions. The fiscal 2027 outlook calls for only 1-6% revenue growth and flat-to-4% operating-profit growth. The planned separation into Wellverse should sharpen strategic focus, but until the business achieves stronger profitability, its slower growth and margin volatility can dilute the contribution from McKesson’s faster-growing oncology and technology businesses.

Regulatory and Policy Changes Create Long-Term Uncertainty: McKesson continues to face uncertainty from evolving healthcare policies, particularly 340B reform and the IRA Part D framework. Management stressed that the current 340B proposal remains under review, making its eventual structure and timing difficult to assess.

The company also noted that IRA Part D changes are not scheduled to take effect until January 2028, with important variables — including maximum fair prices, reimbursement changes and potential biosimilar competition — still unresolved. McKesson believes its scale, technology and compliance capabilities should help it adapt, but policy changes could alter economics across manufacturers, providers, pharmacies and other stakeholders, creating uncertainty around future growth and segment profitability.

McKesson Corporation Price

McKesson Corporation price | McKesson Corporation Quote

Estimate Trends for MCK

McKesson is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings per share has improved 3 cents to $44.64.

The Zacks Consensus Estimate for the company’s second-quarter fiscal 2027 revenues and earnings per share is pegged at $110.14 billion and $10.72, respectively. The estimate for revenues indicates a 6.8% improvement from the year-ago quarter’s reported number, while that for earnings implies an 8.7% gain.

Key Picks

Some better-ranked stocks from the broader medical space are Veracyte (VCYT Quick QuoteVCYT - Free Report) , Globus Medical (GMED Quick QuoteGMED - Free Report) and Intuitive Surgical (ISRG Quick QuoteISRG - Free Report) .

Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

Globus Medical, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.

Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.